Viemed Healthcare Conference Summary Company Overview - **Company**: Viemed Healthcare (NasdaqCM: VMD) - **Market Cap**: Approximately $350 million [3] - **Patient Base**: Over 172,000 patients across 50 states, with significant coverage in 37-38 states [1] Industry Insights - **Core Services**: Complex respiratory services, sleep platform, maternal health, and staffing divisions [1] - **Market Penetration**: - COPD market penetration is around 10% [3] - Sleep business penetration is 20% or less [3] - Overall market share for Viemed in complex respiratory is approximately 14% [6] Financial Performance - **Revenue Growth**: - 2025 revenue was over $270 million, with a 21% growth year-over-year [26] - Projected revenue for 2026 is between $310 million and $320 million [30] - **EBITDA**: Over $60 million in 2025, with guidance for 2026 between $65 million and $69 million [26][30] - **Free Cash Flow**: Generated $28 million in free cash flow in 2025, with expectations for growth in 2026 [2][32] - **Debt Status**: Company remains debt-free on a net basis [26] Growth Strategy - **Organic Growth**: - Company has a 26% CAGR since public inception [2] - Focus on densifying existing markets and expanding into new territories [18] - **M&A Strategy**: - Selective acquisitions aimed at enhancing organic growth [18] - Recent acquisitions include H&P and Lehan's Medical Equipment, which have contributed to growth in maternal health and sleep sectors [20][21] Product Diversification - **Service Mix**: - Ventilators now represent 48% of the business, down from 87% in 2019 [13] - Sleep therapy has grown to 21% of revenue, with a 62% growth rate in CPAP sales [15] - Maternal health now accounts for 6% of revenue, with a 100% growth rate in 2025 [16] - **Technology Utilization**: In-house technology enhances patient care and operational efficiency, including telehealth features for real-time interaction with respiratory therapists [7][9] Regulatory Environment - **Favorable Regulations**: - Exclusion from competitive bidding provides stability [21] - New National Coverage Determinations (NCD) for ventilators clarify treatment rules, reducing ambiguity for payers [23] - **Aging Population**: The demographic trend of baby boomers turning 65 at a rate of 10,000 per day supports demand for home healthcare services [4] Key Performance Metrics - **Growth Metrics**: - 2025 growth rates: - Sleep: 62% - Resupply: 49% - Airway clearance: 18% - Maternal health: 100% [15][16] - **Market Dynamics**: - The company is positioned to capture a significant share of the underserved COPD and sleep apnea markets, with a total addressable market of over 30 million patients for sleep apnea [15][38] Conclusion - **Investment Thesis**: Viemed Healthcare demonstrates strong growth potential through its diversified service offerings, robust financial performance, and favorable regulatory environment, making it an attractive investment opportunity in the healthcare sector [36]

Core Viewpoint - Owens & Minor is transforming into a pure-play company focused on home-based care by selling its Products & Healthcare Services (P&HS) division for $375 million, retaining a 5% stake, marking a strategic shift from supply chain logistics to patient-centric services [2][4][6]. Group 1: Company Transformation - The sale of the P&HS division allows Owens & Minor to redefine its position in the healthcare supply chain, moving from a logistics provider to a direct service provider for patients [2][6]. - The Patient Direct platform, established after acquiring Byram Healthcare in 2020, focuses on home-based care for chronic disease patients, directly connecting to the patient end [7][8]. - The decision to divest the P&HS division is part of a strategy to concentrate on higher-margin, faster-growing segments of the business, enhancing overall financial structure and resource allocation [8][12]. Group 2: Market Context - The U.S. healthcare supply chain has faced declining profit margins, with companies like Owens & Minor experiencing gross margins around 10% and net margins below 2% due to pricing pressures and increased costs [9][10]. - The Patient Direct model offers a more stable and profitable business model, with gross margins 1.5 to 2 times higher than traditional hospital supply chains, appealing to capital markets [9][10]. - The timing of the sale coincides with a resurgence in private equity activity in the healthcare sector, allowing Owens & Minor to achieve favorable pricing while retaining a stake in future growth [14][15]. Group 3: Buyer Perspective - Platinum Equity, the buyer, specializes in operational turnarounds and aims to enhance the value of Owens & Minor's P&HS division through restructuring and resource optimization [16][18]. - The acquisition aligns with Platinum's strategy of integrating and improving underperforming assets in the healthcare supply chain, reflecting a broader trend of private equity involvement in the sector [19][20]. Group 4: Industry Trends - The divestiture by Owens & Minor is part of a larger trend in the medical device industry, where companies are shifting from manufacturing to service-oriented models, emphasizing asset-light operations [22][23]. - The rise of home-based care is driven by policy changes and a growing demand for chronic disease management, positioning companies like Owens & Minor to capitalize on this shift [24][25]. - The transformation reflects a broader industry movement towards decentralization, where patient-centric models are becoming the focal point of healthcare delivery [27][32].